在基中比较光子与质子基于立体体辐射疗法,增加治疗初级细胞癌的最大峰值剂量
Sherif G Shaaban1, Hao Chen2, Anh Tran1
1Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
International journal of particle therapy
|November 24, 2025
概括
与基于光子的SBRT (PH-SBRT) 相比,基于质子的立体体辐射疗法 (PT-SBRT) 为细胞癌提供了更好的目标覆盖和更好的风险器官节省. PT-SBRT显示出更好的功能保护的潜力.
科学领域:
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 基于光子的立体体辐射疗法 (PH-SBRT) 用于细胞癌 (RCC),但可以损害功能和损害附近的器官.
- 优化放射治疗技术对于平衡瘤控制和尽量减少副作用至关重要.
研究的目的:
- 为了比较基于质子 (PT) 的SBRT与用于RCC治疗的PH-SBRT.
- 评估两种技术之间的目标覆盖,危险器官 (OAR) 节省和剂量分配的差异.
主要方法:
- 对PT-SBRT和PH-SBRT计划在125%和142%的最大峰值剂量的比较.
- 使用学生t测试评估目标体积覆盖率 (GTV,CTV) 和OAR剂量.
- 评估与功能相关的指标,特别是侧V50%/Vtot的比率.
主要成果:
- 对PT-SBRT和PH-SBRT的目标覆盖率相似.
- PT-SBRT显著节省了OARs,包括小肠,大肠和未涉及的脏,最大剂量较低,V5-V25 Gy.
- 与膜过率损失相关的异侧V50%/Vtot比,在两种剂量水平 (P < .01) 中,PT-SBRT显著较低.
- 综合剂量在PT-SBRT下较低,高峰剂量允许额外的OAR节省.
结论:
- 与RCC的PH-SBRT相比,PT-SBRT显示出优越的OAR节省和可比的目标覆盖率.
- 质子疗法可以使剂量升级,同时尊重正常组织的限制,潜在地保持功能.
- 需要进一步的前性研究来确认这些好处在临床实践中.
更多相关视频
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
10.4K
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
3.1K
相关概念视频
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
